Description
Biofinity® multifocal is a monthly replacement silicone hydrogel contact lens for patients with presbyopia*.
Features and Benefits
- Balance Progressive® Technology for clear vision at all distances1
- Two different optical designs (D and N) for individualised fitting for each wearer and each eye 1
- High-contrast distance and near visual acuity for 20/20 (or 6/6) 2
- Highly effective fitting process - fit 98% of your patients with two pairs of lenses 3
- Aquaform®Technology for incredible all-day comfort 1
- Naturally wettable material with no need for surface treatments or coatings 1
- The widest silicone hydrogel prescription range that covers 99.7% of (single vision) presbyopes ‡4,5
- Designed by a world leader in multifocal contact lenses†1
![]() | Aquaform®TechnologyAquaform® Technology allows water to be held throughout each Biofinity® lens material, from its core to its surface, helping to keep it moist all day long.1 This provides natural wettability, without coatings or surface treatments to support an incredibly comfortable lens-wearing experience .1 |
![]() | Balance Progressive® Technology1
|
Product Details
-6.50D to -10.00D (0.50D steps)
D-Design
N-Design
Packaging images for illustration purposes only.
* With myopia, hyperopia or emmetropia with presbyopia.
† Combination of 2023 market research based on global volume data and internal estimates. Does not include CooperVision specialty eyecare products.
‡ Based on Rx option combinations (sphere, cylinder, axis & add) manufactured, across all soft lenses in sphere, toric & multifocal (including made to order), in SiHy from 4 main manufacturers. Includes one-day, 2 weekly, and monthly replacement contact lenses. Cosmetic & Photochromatic contact lenses not included. Multiple base curve variants not included.
References:
1. CVI data on file, 2024.
2. Fernandes P et al. Adaptation to multifocal and monovision contact lens correction. Optom Vis Sci. 2013 Mar;90(3):228-35.
3. CVI data on file, 2019. Post-study comparison of CL power recommendation of OptiExpert application with powers determined by ECP in dispensing study with Biofinity multifocal and using the fitting guide. n=55 (110 eyes). DV Rx +1.25D to -3.25D, add powers +1.25 to +2.50DS.
4. CVI data on file, 2023. Industry reports and internal estimates based on Tyler's Quarterly, 12/2022.
5. CVI data on file, 2020. Rx coverage database; 42 to 70 years <0.75DC.
For the device safety, warnings, precaution, and local regulatory information, please refer to the Instruction for Use leaflet.
SA14859 / APP146526